对老年人发生心力衰竭及其亚型的大规模蛋白质基因分析
Joyce N Njoroge1, Sandra Sanders van Wijk2, Thomas R Austin3
1Division of Cardiology, Department of Medicine, Stanford University, Palo Alto, CA (J.N.N.).
Circulation. Genomic and precision medicine
|February 4, 2026
概括
这项研究在老年人中确定了55种心力衰竭 (HF) 和其亚型的新型蛋白质标志物. 七种新蛋白显示可能的因果关系,为改善风险预测和治疗目标提供了潜力.
科学领域:
- 心血管科学 心血管科学
- 蛋白质组学是指蛋白质组学.
- 老年学是指老年学的学科.
背景情况:
- 心力衰竭 (HF),包括HFpEF和HFrEF,显著影响老年人群.
- 评估循环蛋白质组对于理解HF病原和开发新治疗方法至关重要.
研究的目的:
- 在老年人中进行血蛋白质组学查事件HF及其亚型.
- 为了确定与HF,HFpEF和HFrEF相关的新型蛋白质生物标志物.
- 使用孟德尔随机化研究蛋白质和HF亚型之间的潜在因果关系.
主要方法:
- 在使用 SomaLogic 平台的两个大型,基于人口的队列 (CHS 和 AGES-RS) 中进行血蛋白质组查.
- 对考克斯模型进行元分析,以确定与HF,HFpEF和HFrEF的蛋白质关联.
- 在ARIC队列中的复制和因果推理的门德尔随机化.
主要成果:
- 确定了119种与HF相关的蛋白质,15种与HFpEF相关的蛋白质,11种与HFrEF相关的蛋白质.
- 发现了55种新的HF或其亚型的蛋白质标记物,其中7种显示可能的因果关联.
- 在66个已识别的蛋白质中复制了55个外部.
结论:
- 这项大规模的蛋白质组学研究确定了老年人心力衰竭的新型蛋白质标志物.
- 这些发现可能会改善HF风险预测,病理生物学理解和治疗目标优先级.
- 七种蛋白质显示出新的,可能与HF亚型的因果关联.
相关概念视频
01:29Heart Failure II: Pathophysiology
948
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
948
01:17Pathophysiology of Heart Failure
3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
01:27Heart Failure I: Introduction
903
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
01:22Heart Failure VI: Adjunct Therapies
348
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
01:22Heart Failure Drugs: Diuretics
981
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
981
01:30Heart Failure V: Medical Management
329
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
329